Biocorrx (OTCMKTS:BICX – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.02, Zacks reports. The business had revenue of ($0.04) million for the quarter, compared to the consensus estimate of $0.25 million.
Biocorrx Price Performance
Shares of BICX opened at $0.21 on Tuesday. The firm’s 50 day simple moving average is $0.22 and its 200 day simple moving average is $0.30. The company has a market capitalization of $6.41 million, a P/E ratio of -1.74 and a beta of 0.07. Biocorrx has a 1-year low of $0.15 and a 1-year high of $1.28.
Biocorrx Company Profile
BioCorRx, Inc. is a healthcare company focused on substance-use-disorder treatment and related products. Its BioCorRx Recovery Program is an outpatient approach that combines medication-assisted treatment with counseling and ongoing support for people seeking treatment for alcohol or opioid dependence. The company has also pursued pharmaceutical products intended to support addiction treatment, including long-acting formulations. Its business includes developing treatment offerings and working to make them available through healthcare providers.
Read More
- Five stocks we like better than Biocorrx
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
Receive News & Ratings for Biocorrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocorrx and related companies with MarketBeat.com's FREE daily email newsletter.
